[go: up one dir, main page]

WO2002053099A3 - Methods and compositions for treating periodontal disease - Google Patents

Methods and compositions for treating periodontal disease Download PDF

Info

Publication number
WO2002053099A3
WO2002053099A3 PCT/US2001/049638 US0149638W WO02053099A3 WO 2002053099 A3 WO2002053099 A3 WO 2002053099A3 US 0149638 W US0149638 W US 0149638W WO 02053099 A3 WO02053099 A3 WO 02053099A3
Authority
WO
WIPO (PCT)
Prior art keywords
periodontal disease
methods
compositions
present
treating periodontal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/049638
Other languages
French (fr)
Other versions
WO2002053099A2 (en
Inventor
George D Hartman
Sevgi B Rodan
Gideon A Rodan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US10/250,546 priority Critical patent/US20040053968A1/en
Priority to JP2002554050A priority patent/JP2004517853A/en
Priority to CA002432504A priority patent/CA2432504A1/en
Priority to EP01994350A priority patent/EP1349548A4/en
Priority to AU2002246757A priority patent/AU2002246757B2/en
Publication of WO2002053099A2 publication Critical patent/WO2002053099A2/en
Publication of WO2002053099A3 publication Critical patent/WO2002053099A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides for a method for the treatment of alveolar bone loss due to periodontal disease in a subject in need of such treatment comprising administration of a therapeutically effective amount of an αvβ3 integrin receptor antagonist in combination with a therapeutically effective amount of a COX-2 inhibitor. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating the alveolar bone loss due to periodontal disease.
PCT/US2001/049638 2001-01-03 2001-12-28 Methods and compositions for treating periodontal disease Ceased WO2002053099A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/250,546 US20040053968A1 (en) 2001-12-28 2001-12-28 Methods and compositions for treating peridontal disease
JP2002554050A JP2004517853A (en) 2001-01-03 2001-12-28 Method and composition for treating periodontal disease
CA002432504A CA2432504A1 (en) 2001-01-03 2001-12-28 Methods and compositions for treating periodontal disease
EP01994350A EP1349548A4 (en) 2001-01-03 2001-12-28 METHODS AND COMPOSITIONS FOR TREATING PERIODONTOPATHY
AU2002246757A AU2002246757B2 (en) 2001-01-03 2001-12-28 Methods and compositions for treating periodontal disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25944101P 2001-01-03 2001-01-03
US60/259,441 2001-01-03

Publications (2)

Publication Number Publication Date
WO2002053099A2 WO2002053099A2 (en) 2002-07-11
WO2002053099A3 true WO2002053099A3 (en) 2002-09-12

Family

ID=22984959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049638 Ceased WO2002053099A2 (en) 2001-01-03 2001-12-28 Methods and compositions for treating periodontal disease

Country Status (5)

Country Link
EP (1) EP1349548A4 (en)
JP (1) JP2004517853A (en)
AU (1) AU2002246757B2 (en)
CA (1) CA2432504A1 (en)
WO (1) WO2002053099A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
SI3929196T1 (en) 2013-09-24 2023-11-30 Fujifilm Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
ATE298338T1 (en) * 1997-12-17 2005-07-15 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
HUP0302468A2 (en) * 1999-06-02 2003-11-28 Merck & Co., Inc. Alpha v integrin receptor antagonists and pharmaceutical compositions containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1349548A4 *

Also Published As

Publication number Publication date
EP1349548A2 (en) 2003-10-08
AU2002246757B2 (en) 2006-02-02
JP2004517853A (en) 2004-06-17
EP1349548A4 (en) 2004-06-02
CA2432504A1 (en) 2002-07-11
WO2002053099A2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
TW200612987A (en) Combination treatment for non-hematologic malignancies
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
YU71901A (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND beta-MIMETICS
CA2427227A1 (en) Lactam compound
IL151503A0 (en) Therapeutic combinations of antihypertensive and antiagiogenic agents
WO2005107726A3 (en) Method for the treatment of back pain
HUP0303876A3 (en) Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv
UA89615C2 (en) Pharmaceutical compositions comprising nicotinic acid and dp receptor antagonist
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
WO2003080125A3 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
WO2003015690A3 (en) Method for treating primary insomnia
SE9902597D0 (en) New use
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
SE0000303D0 (en) Novel compounds
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2432504

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002246757

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001994350

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10250546

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002554050

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001994350

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2001994350

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001994350

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002246757

Country of ref document: AU